BABeatriz Asenjo

Beatriz Asenjo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beatriz Asenjo has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A multicentre longitudinal brain metastasis imaging dataset with lesion segmentations and clinical data

    by Yahir Y. Calderón-Silva, Julián Pérez-Beteta, David Molina-García, Ismael Fernández-Hernández, José D. Villanueva-García, Beatriz Ocaña-Tienda, Silvia Bordel-Vozmediano, Miguel Perales-Patón, Beatriz Asenjo, David Albillo, et al.

    Brain metastases exhibit substantial variability in lesion burden, morphology and treatment response. Longitudinal imaging linked to lesion annotations and clinical histories can support quantitative studies of this heterogeneity. We describe a multicentre dataset from seven Spanish hospitals comprising 443 patients diagnosed between 2007 and 2022, with follow-up imaging for 216 patients. The collection contains 2842 magnetic resonance image, including 1092 three dimensional (3D) contrast-enhanced T1-weighted, 833 T2-weighted and 917 FLAIR (fluid-attenuated inversion recovery) images. Semiautomatic 3D-segmentation with expert review provides annotations for 1291 unique lesions represented by 2303 lesion observations across imaging time points. Separate labels identify contrast-enhancing and non-enhancing or necrotic tumour components, and lesion identifiers are maintained during follow-up. Accompanying records describe primary tumour characteristics, treatments, imaging dates and clinical outcomes, together with acquisition metadata and 107 morphological and radiomic features. The dataset supports research on lesion detection and segmentation, longitudinal response assessment, imaging biomarkers and mathematical models of brain metastasis growth and treatment response.

  • Deep Learning-Based Brain Lesion Segmentation Across MRI Registration Templates

    by Iván Lago Guerreira, Ariadna Jiménez-Partinen, Beatriz Asenjo, Esteban J. Palomo, Rafael M. Luque-Baena

  • Large-Scale MRI Dataset Curation and Subset Extraction via CNN-Based Sequence and Plane Classification

    by Pedro Fernández-López, Ariadna Jiménez-Partinen, Beatriz Asenjo, Ezequiel López-Rubio, Rafael M. Luque-Baena

  • Open Access

    Intercellular adhesion molecule 1 links glioblastoma biology to a scalable prognostic model integrating clinical, imaging, and molecular features

    by Shreya Gandhi, Beatriz Ocaña-Tienda, Manuel M Bettencourt, Olivia S Singh, Kaviya Devaraja, Emily R Irish, David Molina-García, Shirin Karimi, Yasin Mamatjan, Julio Sosa, et al.

    Background: Glioblastoma (GB) exhibits marked tumor microenvironmental heterogeneity, contributing to both therapy resistance and poor survival outcomes. Intercellular adhesion molecule 1 (ICAM1) is an inflammation-associated adhesion molecule implicated in immune-stromal interactions, but its clinical and biological significance in GB remains incompletely defined. Methods: We performed ICAM1 immunohistochemistry, bulk RNA sequencing, DNA methylation analysis, single-nucleus RNA sequencing, and preoperative MRI-derived morphologic feature analysis across multi-institutional cohorts of treatment-naïve IDH-wildtype GB. Results: High ICAM1 expression at both transcript and protein levels is associated with shorter overall survival, particularly within the mesenchymal transcriptional subtype. ICAM1 expression is inversely associated with promoter methylation. Single-nucleus RNA-sequencing analysis shows that ICAM1-high tumors are enriched for mesenchymal, hypoxia, stress-associated, and immunosuppressive myeloid programs, suggesting that ICAM1 reflects a multicompartment inflammatory tumor ecosystem. ICAM1 expression, tumor surface irregularity, and patient age are independently prognostic and minimally correlated, capturing complementary clinical, imaging, and molecular features of GB biology. When combined, our Clinical-Imaging-Molecular (CIM) framework refines outcome prediction across independent GB cohorts using routinely available clinical data, conventional imaging, and standard immunohistochemistry. Conclusions: ICAM1 characterizes an immune-remodeled, stress-adapted GB ecosystem associated with poor clinical outcomes. Integrating patient age, surface irregularity, and ICAM1 expression yields a scalable and clinically accessible prognostic framework for GB, supporting tailored outcome prediction, particularly in low- and middle-resource settings without routine access to advanced molecular profiling.

  • Open Access

    A clinical decision-support framework to differentiate radiation necrosis from tumor progression in brain metastases

    by Beatriz Ocaña-Tienda, Zhao Hui Chen Zhou, Ana Ramos, Ana Ortiz de Mendivil, Fatima Nagib-Raya, Beatriz Asenjo, Alberto Bastero, Carlos Tramblin, Estanislao Arana, Víctor M Pérez-García

    Background: Differentiating radiation necrosis (RN) from tumor progression (TP) after stereotactic radiotherapy (SRT) in brain metastases (BMs) is a clinically consequential problem, as conventional MRI frequently fails to distinguish between them. Misclassification can lead to inappropriate treatment decisions or delayed therapy. The objective of this study was to develop a clinically interpretable, data-driven model that integrates lesion growth dynamics with routinely available clinical variables to improve discrimination between RN and TP. Methods: We retrospectively analyzed 175 BMs from 6 institutions. Lesion volumes were extracted from three consecutive contrast-enhanced T1-weighted MRI, and growth dynamics were quantified by estimating the growth exponent β. Clinical and treatment-related variables were systematically evaluated, and a multivariable predictive model was trained on a development cohort (n = 131) and validated on an external cohort (n = 44). Results: The final model combined β, primary tumor histology, and SRT modality. In the development cohort, the model demonstrated strong discriminative performance (AUC = 0.887). External validation confirmed generalizability, achieving an overall accuracy of 0.75, with high specificity (0.85) and positive predictive value (0.92) for RN. Incorrect classifications were largely confined to an intermediate-probability zone, while predictions at low and high probability extremes were highly reliable. The model was translated into a freely accessible, web-based tool to facilitate clinical decision-making. Conclusions: By integrating lesion growth dynamics with routine clinical variables, this probability-based framework supports clinically meaningful differentiation between RN and TP. Its ability to explicitly represent diagnostic uncertainty, together with external validation, highlights its potential utility as a decision-support tool in the management of BMs.

  • Open Access

    Latent diffusion for arbitrary zoom MRI super-resolution

    by Jorge Andrés Mármol-Rivera, José David Fernández-Rodríguez, Beatriz Asenjo, Ezequiel López-Rubio


  • Open Access

    Volumetric analysis: Rethinking brain metastases response assessment

    by Beatriz Ocaña-Tienda, Julián Pérez-Beteta, José Antonio Romero-Rosales, Beatriz Asenjo, Ana Ortiz de Mendivil, Luis Alberto Pérez Romasanta, Jose David Albillo Labarra, Fátima Nagib, María Vidal Denis, Belén Luque, et al.

    Background: The Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) criteria are the gold standard for assessing brain metastases (BMs) treatment response. However, they are limited by their reliance on 1D, despite the routine use of high-resolution T1-weighted MRI scans for BMs, which allows for 3D measurements. Our study aimed to investigate whether volumetric measurements could improve the response assessment in patients with BMs. Methods: We retrospectively evaluated a dataset comprising 783 BMs and analyzed the response of 185 of them from 132 patients who underwent stereotactic radiotherapy between 2007 and 2021 at 5 hospitals. We used T1-weighted MRIs to compute the volume of the lesions. For the volumetric criteria, progressive disease was defined as at least a 30% increase in volume, and partial response was characterized by a 20% volume reduction. Results: Our study showed that the proposed volumetric criteria outperformed the RANO-BM criteria in several aspects: (1) Evaluating every lesion, while RANO-BM failed to evaluate 9.2% of them. (2) Classifying response effectively in 140 lesions, compared to only 72 lesions classified by RANO-BM. (3) Identifying BM recurrences a median of 3.3 months earlier than RANO-BM criteria. Conclusions: Our study demonstrates the superiority of volumetric criteria in improving the response assessment of BMs compared to the RANO-BM criteria. Our proposed criteria allow for evaluation of every lesion, regardless of its size or shape, better classification, and enable earlier identification of progressive disease. Volumetric criteria provide a standardized, reliable, and objective tool for assessing treatment response.


  • Open Access

    Growth dynamics of brain metastases differentiate radiation necrosis from recurrence

    by Beatriz Ocaña-Tienda, Julián Pérez-Beteta, David Molina-García, Beatriz Asenjo, Ana Ortiz de Mendivil, David Albillo, Luís A Pérez-Romasanta, Elisabeth González del Portillo, Manuel Llorente, Natalia Carballo, et al.

    Background: Radiation necrosis (RN) is a frequent adverse event after fractionated stereotactic radiotherapy (FSRT) or single-session stereotactic radiosurgery (SRS) treatment of brain metastases (BMs). It is difficult to distinguish RN from progressive disease (PD) due to their similarities in the magnetic resonance images. Previous theoretical studies have hypothesized that RN could have faster, although transient, growth dynamics after FSRT/SRS, but no study has proven that hypothesis using patient data. Thus, we hypothesized that lesion size time dynamics obtained from growth laws fitted with data from sequential volumetric measurements on magnetic resonance images may help in discriminating recurrent BMs from RN events. Methods: A total of 101 BMs from different institutions, growing after FSRT/SRS (60 PDs and 41 RNs) in 86 patients, displaying growth for at least 3 consecutive MRI follow-ups were selected for the study from a database of 1031 BMs. The 3 parameters of the Von Bertalanffy growth law were determined for each BM and used to discriminate statistically PDs from RNs. Results: Growth exponents in patients with RNs were found to be substantially larger than those of PD, due to the faster, although transient, dynamics of inflammatory processes. Statistically significant differences (P < .001) were found between both groups. The receiver operating characteristic curve (AUC = 0.76) supported the ability of the growth law exponent to classify the events. Conclusions: Growth law exponents obtained from sequential longitudinal magnetic resonance images after FSRT/SRS can be used as a complementary tool in the differential diagnosis between RN and PD.


  • Open Access

    The Growth Laws of Brain Metastases

    by Beatriz Ocaña-Tienda, Julián Pérez-Beteta, David Molina-García, Juan Jiménez-Sánchez, Odelaisy Leon-Triana, Ana Ortiz de Mendivil, Beatriz Asenjo, David Albillo, Luís A. Pérez-Romasanta, Manuel Valiente, et al.

    Tumor growth is the result of the interplay of complex biological processes in huge numbers of individual cells living in changing environments. Effective simple mathematical laws have been shown to describe tumor growth in vitro, or simple animal models with bounded-growth dynamics accurately. However, results for the growth of human cancers in patients are scarce. Our study mined a large dataset of 1133 brain metastases (BMs) with longitudinal imaging follow-up to find growth laws for untreated BMs and recurrent treated BMs. Untreated BMs showed high growth exponents, most likely related to the underlying evolutionary dynamics, with experimental tumors in mice resembling accurately the disease. Recurrent BMs growth exponents were smaller, most probably due to a reduction in tumor heterogeneity after treatment, which may limit the tumor evolutionary capabilities. In silico simulations using a stochastic discrete mesoscopic model with basic evolutionary dynamics led to results in line with the observed data.